Generex: Experimental cancer vaccine is 'safe, well-tolerated'

WORCESTER, Mass. Data from an early-stage clinical trial presented at the annual meeting of the American Society of Clinical Oncology indicate that an experimental vaccine for prostate cancer is safe, well-tolerated and produces the desired response, the vaccine’s manufacturer announced Monday.

Generex Biotechnology Corp. said results of a phase 1 trial of the immunotherapeutic peptide AE37, developed by subsidiary Antigen Express, were consistent with those of prior clinical trials of the vaccine in breast cancer patients. The vaccine is currently undergoing phase 2 studies in breast cancer patients.

The study took place in Athens, Greece.